BCAT2 Inhibitors
BCAT2 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the enzyme branched-chain amino acid transaminase 2 (BCAT2). BCAT2 is a mitochondrial enzyme that catalyzes the reversible transamination of branched-chain amino acids (BCAAs), such as leucine, isoleucine, and valine, converting them into their corresponding keto acids. This process is essential for maintaining amino acid homeostasis and is a critical step in the catabolic pathway of BCAAs. By inhibiting BCAT2, these compounds block the transamination reaction, leading to disruptions in the normal metabolic processing of BCAAs. As a result, BCAT2 inhibitors are valuable tools for studying the metabolism of BCAAs and the regulation of amino acid levels in cells.
The design of BCAT2 inhibitors involves creating molecules that bind to the active site of the BCAT2 enzyme, preventing it from interacting with its substrates. These inhibitors are often developed through structure-activity relationship (SAR) studies to enhance their selectivity and affinity for BCAT2, ensuring they do not interfere with other enzymes involved in amino acid metabolism. The inhibition of BCAT2 can lead to changes in cellular metabolism, particularly in tissues where BCAA metabolism plays a significant role, such as muscle and liver. By using BCAT2 inhibitors in biochemical research, scientists can better understand the metabolic pathways involving BCAAs and how the regulation of these pathways impacts broader cellular functions, including energy production, protein synthesis, and nitrogen balance within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A could downregulate BCAT2 expression by inhibiting histone deacetylase, leading to a more condensed chromatin state and reduced transcription initiation of the BCAT2 gene. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine may decrease BCAT2 expression through DNA demethylation at the gene promoter, thereby diminishing the binding of transcription repressors. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin could lead to a decrease in BCAT2 expression by inhibiting the mTOR pathway, which is crucial for protein synthesis and cell growth, potentially reducing the transcription of the BCAT2 gene. | ||||||
Chloramphenicol | 56-75-7 | sc-3594 | 25 g | $90.00 | 10 | |
Chloramphenicol might reduce BCAT2 expression by inhibiting mitochondrial protein synthesis, which is essential for maintaining BCAT2 enzyme levels in mitochondria. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid could downregulate BCAT2 expression by activating retinoic acid receptors that bind to the BCAT2 gene promoter, altering gene transcription. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 may decrease BCAT2 expression by inhibiting PI3K, leading to a disruption of downstream signaling pathways critical for the gene's expression. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate could downregulate BCAT2 by acting as an HDAC inhibitor, which may lead to increased histone acetylation and a reduction in BCAT2 gene transcription. | ||||||
Oxamic acid | 471-47-6 | sc-250620 | 25 g | $148.00 | ||
Oxamic acid may reduce BCAT2 expression by competitively inhibiting lactate dehydrogenase, leading to an alteration in pyruvate metabolism which could signal a decrease in BCAT2 transcription. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
Metformin may decrease BCAT2 expression through activation of AMPK, promoting a cellular state that conserves energy and potentially suppresses energy-intensive biosynthetic processes, including BCAT2 transcription. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
Disulfiram might inhibit BCAT2 expression by interfering with acetaldehyde dehydrogenase, causing an accumulation of acetaldehyde that could downregulate the transcription of BCAT2 due to cellular stress responses. | ||||||